Avraham Raz

Avraham Raz

Auto-generated profile, based on publicly available information

Avraham Raz

Department of Oncology, Karmanos Cancer Institute, School of Medicine, Wayne State University, Detroit, Michigan, USA

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2002 in Glycoconjugate Journal
Verified
Journal Article
Closed access
PDF file
YTYukinori Takenaka
Yukinori Takenaka
TFTomoharu Fukumori
Tomoharu Fukumori
ARAvraham Raz
Avraham Raz

1 September 2009 in Carbohydrate Research
Verified
Journal Article
Closed access
VGVladislav V. Glinsky
Vladislav V. Glinsky
ARAvraham Raz
Avraham Raz

1 March 2005 in Apoptosis
Verified
Journal Article
Closed access
PDF file
SNS. Nakahara
S. Nakahara
NON. Oka
N. Oka
ARA. Raz
A. Raz

1 May 2004 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
YTYukinori Takenaka
Yukinori Takenaka
TFTomoharu Fukumori
Tomoharu Fukumori
TYTadashi Yoshii
Tadashi Yoshii
NONatsuo Oka
Natsuo Oka
HIHidenori Inohara
Hidenori Inohara
ARAvraham Raz
Avraham Raz
Galectin-3 (Gal-3), a member of the β-galactoside binding protein family containing the NWGR antideath motif of the Bcl-2 protein family, is involved in various aspects of cancer progression. Previously, it has been shown that the antiapoptotic activity of Gal-3 is regulated by the phosphorylation at Ser6 by casein kinase 1 (CK1). Here we questioned how phosphorylation at Ser6 regulates Gal-3 function. We have generated serine-to-alanine (S6A) and serine-to-glutamic acid (S6E) Gal-3 mutants and transfected them into the BT-549 human breast carcinoma cell line, which does not express Gal-3. BT-549 cell clones expressing wild-type (wt) and mutant Gal-3 were exposed to chemotherapeutic anticancer drugs. In response to the apoptotic insults, phosphorylated wt Gal-3 was exported from the nucleus to the cytoplasm and protected the BT-549 cells from drug-induced apoptosis while nonphosphorylated mutant Gal-3 neither was exported from the nucleus nor protected BT-549 cells from drug-induced apoptosis. Furthermore, leptomycin B, a nuclear export inhibitor, increased the cisplatin-induced apoptosis of Gal-3 expressing BT-549 cells. These results suggest that Ser6 phosphoryaltion acts as a molecular switch for its cellular translocation from the nucleus to the cytoplasm and, as a result, regulates the antiapoptotic activity of Gal-3.

5 January 2018 in Glycobiology
Verified
Journal Article
Open access
PDF file
PNPratima Nangia-Makker
Pratima Nangia-Makker
VHVictor Hogan
Victor Hogan
ARAvraham Raz
Avraham Raz
Over the last few decades galectin-3, a carbohydrate binding protein, with affinity for N-acetyllactosamine residues, has been unique due to the regulatory roles it performs in processes associated with tumor progression and metastasis such as cell proliferation, homotypic/heterotypic aggregation, dynamic cellular transformation, migration and invasion, survival and apoptosis. Structure–function association of galectin-3 reveals that it consists of a short amino terminal motif, which regulates its nuclear-cytoplasmic shuttling; a collagen α-like domain, susceptible to cleavage by matrix metalloproteases and prostate specific antigen; accountable for its oligomerization and lattice formation, and a carbohydrate-recognition/binding domain containing the anti-death motif of the Bcl2 protein family. This structural complexity permits galectin-3 to associate with numerous molecules utilizing protein–protein and/or protein–carbohydrate interactions in the extra-cellular as well as intracellular milieu and regulate diverse signaling pathways, a number of which appear directed towards epithelial–mesenchymal transition and cancer stemness. Self-renewal, differentiation, long-term culturing and drug-resistance potential characterize cancer stem cells (CSCs), a small cell subpopulation within the tumor that is thought to be accountable for heterogeneity, recurrence and metastasis of tumors. Despite the fact that association of galectin-3 to the tumor stemness phenomenon is still in its infancy, there is sufficient direct evidence of its regulatory roles in CSC-associated phenotypes and signaling pathways. In this review, we have highlighted the available data on galectin-3 regulated functions pertinent to cancer stemness and explored the opportunities of its exploitation as a CSC marker and a therapeutic target.

1 December 2003
Verified
Journal Article
Closed access
TFTomoharu Fukumori
Tomoharu Fukumori
YTYukinori Takenaka
Yukinori Takenaka
TYTadashi Yoshii
Tadashi Yoshii
Hyeong-Reh KimHyeong-Reh Kim
Hyeong-Reh Kim
VHVictor Hogan
Victor Hogan
ARAvraham Raz
Avraham Raz